Antimicrobial Resistance Action Fund

Antimicrobial Resistance Action Fund is sponsored by AMR Action Fund (organized by IFPMA, funded by pharmaceutical companies and other partners). The AMR Action Fund is the world's largest venture capital fund dedicated to investing in urgently needed antimicrobial therapeutics.

Partnerships and alliances | The industry-led AMR Action Fund organized by IFPMA is a groundbreaking USD 1 billion initiative that aims to bring 2-4 new antibiotics to patients by 2030. The AMR Action Fund is the world’s largest venture capital fund dedicated to investing in urgently needed antimicrobial therapeutics.

The concept for an investment fund to support companies developing potentially lifesaving antimicrobial therapeutics originated in conversations among the International Federation of Pharmaceutical Manufacturers and Associations, its Biopharmaceutical CEOs Roundtable (BCR) , the World Health Organization, the European Investment Bank, and the Wellcome Trust.

Besides investing in the development of new antibiotics, the AMR Action Fund works with partners to create market conditions that enable sustainable investment in the antibiotic pipeline. AMR Action Fund objectives Launched in 2020, the AMR Action Fund expects to raise more than USD 1 billion.

This will be used to invest in smaller biotech companies and to provide industry expertise to support the clinical development of new antibiotics. It will strengthen and accelerate the research and development (R&D) of antibiotics through investment and providing industry resources and expertise to biotechnology companies.

But, while the Fund is helping to bridge the clinical funding gap, it cannot address the fundamental problem: not enough antibiotics are being produced.

innovative pharmaceutical companies from Europe, the US, and Japan helped fund the AMR Action Fund expected to be raised by the Fund in total, including from outside the industry investments made by the Fund so far Why the AMR Action Fund is needed It’s widely agreed that market-based policy reforms, including reimbursement reform and new incentives, are required to create market conditions that enable sustainable investment in antibiotic R&D.

Investment in developing new antibiotics is falling because, despite the vast societal costs of AMR, there is no viable market for new antibiotics. This is because new antibiotics are used sparingly to preserve effectiveness, so developers don’t have a chance to recoup their investment.

The result is an enormous public health need for new antibiotics, but a lack of funding for antibiotic R&D, especially the later stages of clinical research. In April 2022, the AMR Action Fund announced its first two investments, in There are simply not enough antibiotics in development, which has created a “valley of death” between discovery and patients.

Although the innovative pharmaceutical industry is being proactive, governments must act decisively to revitalize the antibiotics market and make sure the pipeline meets patient needs. Policymakers across the globe must make market-based reforms to create an environment where antibiotic R&D can flourish in future.

We appreciate the work of initiatives including… the nascent industry-led AMR Action Fund to support the development and approval of much-needed innovative antimicrobial therapeutics.

G7 Health Ministers’ Meeting, communique, Race Against Resistance, a new film by BBC StoryWorks with support from AMR Action Fund, goes inside the lives of the patients and clinicians on the frontlines of the global AMR crisis to show what's at stake if antibiotics fail.

Revitalizing the antibiotic pipeline by implementing new R&D pull incentives With the 2024 UN High-Level Meeting on antimicrobial resistance (AMR) and its political declaration, together with the biennial AMR Ministerial Meeting, the world has set an ambitious agenda to tackle AMR. The next four years offer renewed political momentum to deliver progress ahead of the next UN High-Level Meeting on AMR in 2029.

A central priority is creating the necessary policy frameworks that stimulate R&D investment. This brief identifies the key barriers to antibiotic R&D and the policy measures needed to address them. Sustainable, effective pull incentives are urgently required to ensure a reliable pipeline of new antibiotics for patients and health systems.

We set out how these incentives should be designed and implemented, guided by a set of core principles to maximize their impact. Investing, building, advocating The AMR Action Fund is enabling exciting breakthroughs in antimicrobials. Find out how you can connect with the Fund.

Related news and resources New AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment of US$1 billion New AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment of US$1 billion. This partnership aims to bring 2 to 4 new antibiotics to patients by the end of the decade and facilitate needed long-term policy solutions.

Launch Event 9 July | New initiative takes on the antibiotic innovation challenge The world is losing its most powerful tool in healthcare: antibiotics. The reason is rapidly rising antibiotic-resistant infections – also called antimicrobial resistance, or AMR.

Message from Thomas Cueni at AMR Action Fund launch event in Tokyo on 10 July 2020 Other partnerships and alliances Coalition for Access to NCD Medicines & Products The Coalition for Access to NCD Medicines & Products is a multisectoral alliance that seeks to address gaps in access to affordable medicines and products for noncommunicable diseases.

IFPMA supports IQN Path, a leading international consortium working to improve the quality and reach of biomarker testing – an essential foundation for precision oncology. IFPMA is a partner of Business at OECD's Stronger Together campaign which aims to emphasize the central role of health in achieving economic security. Enter your Mastodon instance URL (optional)